tox data this quarter, CNS pushed to end of year in recent update, leaving the entities some more time to let the share appreciate at accumulation friendly pace. Tox data should give a boost but CNS should be the big news, particularly since we operate on that front in stealth like our good friends at Roche.
EOY price should be back to square one at 17 cents with strong price development when we are in human trials early next year, all IMO
News: PYC Pyc Therapeutics Says FY Loss Attributable A$13.9 Million, page-41
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.020(1.77%) |
Mkt cap ! $670.7M | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.18 | $1.11 | $172.3K | 151.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 592 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 4211 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |